Abstract: The present application relates to a method of producing drimenol and/or drimenol derivatives by comprising contacting at least one polypeptide with farnesyl diphosphate (FPP). The method may be performed in vitro or in vivo. Also provided are amino acid sequences of polypeptides useful in the methods and nucleic acids encoding the polypeptides described. The method further provides host cells or organisms genetically modified to express the polypeptides and useful to produce drimenol and/or derivatives of drimenol.

Abstract: The present invention relates to compositions such as cleaning compositions comprising enzymes. The invention further relates, use of compositions comprising such enzymes in cleaning processes.

Abstract: ?2-6-Sialyltransferase (2,6ST) variants having improved ?2-6-specific sialidase activity as compared to the native 2,6ST enzymes are described. The variants include GT80 sialyltransferases such as P. damselae Pd2,6ST. Methods for making de-sialylated products and screening sialidase activity are also described.

Abstract: Described is a method for the preparation of a gelatin hydrolysate having a decreased endotoxin content, comprising the steps of incubating a solution of gelatin of gelatin hydrolysate at a temperature of 70-125° C. at a pH of 3.5 or less for a time period of at least 15 minutes, and recovering the gelatin hydrolysate. Further a gelatin hydrolysate thus obtained is described.

Abstract: Fungi that are genetically inactivated for the mstC gene (or a homolog thereof) are provided, which can also be genetically modified to increase production of heterologous proteins from a glucoamylase promoter. Methods of using these fungi, for example to degrade a biomass, are also provided.

Abstract: The invention relates to a recombinant Escherichia coli expressing a fusion protein of formamidase and phosphite dehydrogenase, a construction method and use thereof. The invention includes adopting engineered E. coli DH5? as a host, amplifying a cloned formamidase gene and a cloned phosphite dehydrogenase gene into a fusion gene, ligating the fusion gene to a multiple cloning site of a vector, transforming the obtained recombinant plasmid into the E. coli DH5?, extracting the plasmid and transforming into an expression strain, and performing induction culture to obtain a recombinant E. coli. The recombinant E. coli can express a fusion protein of formamidase and phosphite dehydrogenase.

Abstract: The present application relates to the technical field of genetic engineering, and provides a monooxygenase mutant, a preparation method and application thereof. The monooxygenase mutant has any one of the amino acid sequences shown in (I) and (II): (I) an amino acid sequence having at least 80% identity with the amino acid sequence shown in SEQ ID NO. 1; and (II) an amino acid sequence obtained by modifying, substituting, deleting, or adding one or several amino acids to the amino acids at 23 to 508 positions of the amino acid sequence shown in SEQ ID NO. 1, the substituting referring to a substitution of 1 to 34 amino acids, wherein the mutant has the activity of monooxygenase.

Abstract: The invention relates to fusion polypeptides, nucleic acid molecules encoding said fusion polypeptides and genetically modified cells including said nucleic acid molecules. Moreover, the invention relates to a method for preparing target polypeptides using the fusion polypeptides.

Abstract: The present disclosure relates to a variant of cAMP receptor protein of Escherichia coli with alanine at position 35, a microorganism including the same, and a method of producing an L-amino acid using the same.

Abstract: This disclosure provides methods and landing pad constructs for generation of parental cell lines suitable for targeted integration. A method is provided by the parental cell line development; this is, the introduction of binding sites of BPV1 E2 protein to landing pad vectors so that expressed BPV1 E2 protein could locate the vector to transcriptionally active region in the genome. Cells with high expression level of reporter genes are selected for the next stage and will be used in the development of cell lines expressing another recombinant protein by recombination mediated cassette exchange (RMCE). Landing pad constructs include recombination target sites for site-specific recombinases, and therefore, it could be replaced with gene-of-interest expression construct containing the same set of recombination target sites. This yields the generation of producer cell lines with less effort compared to traditional cell line development by random integration.

Abstract: Provided herein are methods for the improved production of periplasmic-targeted recombinant proteins in E. coli host strains. Also provided are E. coli host strains with improved capacity for producing recombinant proteins.

Abstract: Disclosed herein is a process for producing a recombinant Candida cell, which involves genetically engineering a parent Candida cell using a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas)(CRISPR/Cas) system. A recombinant Candida cell obtained using the process and a method for producing D-lactic acid from a biomass using the recombinant Candida cell are also disclosed.

Abstract: An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.

Abstract: The present disclosure discloses Microbacterium oleivorans capable of degrading polyethylene terephthalate and an intermediate thereof, and belongs to the technical field of microorganisms. The present disclosure provides Microbacterium oleivorans JWG-G2 capable of degrading the polyethylene terephthalate. After Microbacterium oleivorans JWG-G2 is inoculated into an inorganic salt liquid medium containing 2 g/L polyethylene terephthalate plastic particles with an inoculation quantity of 1×108 CFU/mL to be cultivated for 5 d, the polyethylene terephthalate plastic particles can be partially degraded into monohydroxyethyl terephthalate and terephthalic acid capable of being directly recycled, ester bond functional groups on surfaces of the polyethylene terephthalate plastic particles can be reduced, and a weight loss ratio of the polyethylene terephthalate plastic particles can reach 5.6%.

Abstract: The present invention relates to a coupled biotransformation process of converting chenodeoxycholic acid (CDCA) and related compounds to ursodeoxycholic acid (UDCA) and related compounds. It also relates to the cloning, expression, and biochemical characterization of a novel NADP+-dependent 7?-hydroxysteroid dehydrogenase (7?-HSDH) from Clostridium difficile, cofactor switch mutants thereof, and their application for the oxidation of bile acids. A further aspect of the invention relates to novel NADP-dependent cofactor switch mutants of the NADP+-dependent 7?-HSDH of E. coli and their application for the oxidation of bile acids.

Abstract: Provided are an L-glutamate dehydrogenase mutant and an application thereof, the mutant mutating the amino acid residue A at position 166 and/or the amino acid residue V at position 376 shown in SEQ ID NO. 1 into a hydrophilic or small sterically hindered amino acid residue, the application performing an amination reaction of 2-oxo-4-(hydroxymethylphosphinyl)butyrate in the presence of an L-amino acid dehydrogenase mutant, an inorganic amino donor, and a reduced coenzyme NADPH, and performing an acidification reaction on the obtained L-glufosinate salt to obtain L-glufosinate. Compared to wild L-glutamate dehydrogenase, the present L-glutamate dehydrogenase mutant has a higher concentration of substrates that can be catalysed when preparing L-glufosinate, thereby increasing the efficiency of the action of the enzyme and reducing reaction costs.

Abstract: Disclosed herein are genetically modified microorganisms and related methods for enhanced utilization of oligosaccharides and improved productivity of compounds derived from the metabolism of the oligosaccharides. The microorganisms described herein have altered activities of plasma membrane ATPase protein (PMA1) and/or one or more extracellular glucose sensors, namely, sucrose non-fermenting protein (SNF3), restores glucose transport protein (RGT2), and G protein-coupled receptor 1 protein (GPR1). These genetic modifications provide the microorganisms an increased ability to utilize an oligosaccharide to produce a compound of interest, particularly, tagatose, 2?-fucosyllactose, and psicose. Methods of culturing the microorganisms in the presence of such oligosaccharides to produce the products of interest are also provided.

Abstract: The present invention discloses a strain of Pseudomonas aeruginosa with monomethylamine degradability and the application thereof. This strain, named Pseudomonas aeruginosa GDUTAN1, was deposited on May 24, 2017 in the China Center for Type Culture Collection in Wuhan University, Wuhan City, Hubei Province with a deposit number of CCTCC NO.: M 2017283. This Pseudomonas aeruginosa GDUTAN1 was Gram-negative and rod-like, and round, green and opaque in the colony morphology, having a diameter of 1-2 mm. The Pseudomonas aeruginosa GDUTAN1 of the present invention can be applied to environmental remediation, degrading monomethylamine in the environment at a high degradation efficiency. When it degrades monomethylamine for 96 h at a substrate concentration of 50-140 mg/L, the degradation efficiency can reach more than 99%.

Abstract: The present application relates to recombinant microorganisms useful in the biosynthesis of monoethylene glycol (MEG) or glycolic acid (GA), or MEG and one or more co-product, from one or more pentose and/or hexose sugars. Also provided are methods of producing MEG (or GA), or MEG (or GA) and one or more co-product, from one or more pentose and/or hexose sugars using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or the products MEG (or GA), or MEG and one or more co-product.

Abstract: Variant guinea pig L-asparaginases which are truncated and humanized are described as are fusion proteins containing the L-asparaginase and use of the L-asparaginases in the treatment of cancers such as acute lymphoblastic leukemia and acute myeloid leukemia.